olanzapine

oh-LAN-za-peen

Therapeutic Classification: antipsychotics, mood stabilizers

Pharmacologic Classification: thienobenzodiazepines

IM: IM:

BEERS REMS

PO: Schizophrenia.
PO: Management of the following:
- Acute therapy of manic or mixed episodes associated with bipolar I disorder (as monotherapy [adults and adolescents] or in combination with lithium or evaporate [adults only]);
- Maintenance therapy of bipolar I disorder;
- Depressive episodes associated with bipolar I disorder (in combination with fluoxetine);
- Treatment-resistant depression (in combination with fluoxetine).
Acute agitation due to schizophrenia or bipolar I mania.

Unlabeled Use:

Anorexia nervosa.
Treatment of nausea and vomiting related to highly emetogenic chemotherapy.

Antagonizes dopamine and serotonin type 2 in the CNS.
Also has anticholinergic, antihistaminic, and anti–alpha₁-adrenergic effects.

Therapeutic effects:

Decreased manifestations of psychoses.

Absorption: Well absorbed but rapidly metabolized by first-pass effect, resulting in 60% bioavailability. Conventional tablets and orally disintegrating tablets (Zydis) are bioequivalent. IM administration results in significantly higher blood levels (5 times that of oral).

Distribution: Extensively distributed.

Protein Binding: 93%.

Metabolism/Excretion: Primarily metabolized by the liver by the CYP1A2 isoenzyme; 7% excreted unchanged in urine.

Half-Life: 21–54 hr.

( antipsychotic effects)

ROUTE		ONSET		PEAK*		DURATION
PO		unknown		6 hr		unknown
IM		rapid		15–45 min		2–4 hr

* Blood levels.

Contraindicated in:

Hypersensitivity;
Phenylketonuria (orally disintegrating tablets contain aspartame).

Use Cautiously in:

Hepatic impairment;
Patients at risk for aspiration or falls;
Cardiovascular or cerebrovascular disease;
History of seizures;
History of attempted suicide;
Diabetes or risk factors for diabetes (may worsen glucose control);
Presence/history of constipation, urinary retention, prostatic hypertrophy, or paralytic ileus;
Low WBC or ANC or history of drug-induced neutropenia/leukopenia;
Angle-closure glaucoma;
History of breast cancer;
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk; neonates at ↑ risk for extrapyramidal symptoms and withdrawal after delivery when exposed during the 3rd trimester;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential fetal risk;
Pedi: Children <13 yr (safety and effectiveness not established); adolescents at ↑ risk for weight gain and hyperlipidemia;
Geri: Appears on Beers list. ↑ risk of stroke, cognitive decline, and mortality in older adults with dementia. Avoid use in older adults, except for schizophrenia, bipolar disorder, or adjunctive treatment of major depressive disorder.

CV: orthostatic hypotension, bradycardia, chest pain, syncope, tachycardia

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), photosensitivity

EENT: amblyopia, rhinitis, ↑salivation, pharyngitis

Endo: galactorrhea, goiter, gynecomastia, hyperglycemia, hyperprolactinemia

F and E: ↑thirst

GI: ↑liver enzymes, constipation, dry mouth, weight loss, abdominal pain, dysphagia, nausea

GU: ↓fertility (women), ↓libido, amenorrhea, impotence, urinary incontinence

Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia

Metab: weight gain, ↑appetite, dyslipidemia

MS: hypertonia, joint pain

Neuro: agitation, delirium, dizziness, headache, restlessness, sedation, tremor, weakness, dystonia, falls, insomnia, mood changes, NEUROLEPTIC MALIGNANT SYNDROME, personality disorder, SEIZURES, speech impairment, SUICIDAL THOUGHTS, tardive dyskinesia

Resp: aspiration, cough, dyspnea

Misc: body temperature dysregulation, fever, flu-like syndrome

Drug-drug:

↑CNS depression may occur with concurrent use of alcohol or other CNS depressants; concurrent use of IM olanzapine and parenteral benzodiazepines should be avoided.
↑anticholinergic effects with other anticholinergic drugs, including antihistamines, quinidine, disopyramide, and antidepressants; avoid concurrent use.
Effects may be ↓ by carbamazepine, omeprazole, or rifampin.
Antihypertensives and CNS depressants may ↑ risk of orthostatic hypotension.
May antagonize the effects of levodopa or other dopamine agonists.
Fluvoxamine may ↑ levels and risk of toxicity.
Nicotine can ↓ levels and effectiveness.

Schizophrenia

PO (Adults ): 5–10 mg/day initially; may ↑ at weekly intervals by 5 mg/day (target dose = 10 mg/day; not to exceed 20 mg/day).
PO (Adults Debilitated or Nonsmoking Female Patients ≥65 yr): Initiate therapy at 5 mg/day.
PO (Children 13–17 yr): 2.5–5 mg/day initially; may ↑ at weekly intervals by 2.5–5 mg/day (target dose = 10 mg/day; not to exceed 20 mg/day).
IM (Adults ): Oral olanzapine dose = 10 mg/day: 210 mg every 2 wk or 410 mg every 4 wk for the 1st 8 wk, then 150 mg every 2 wk or 300 mg every 4 wk as maintenance therapy; Oral olanzapine dose = 15 mg/day: 300 mg every 2 wk for the 1st 8 wk, then 210 mg every 2 wk or 405 mg every 4 wk as maintenance therapy; Oral olanzapine dose = 20 mg/day: 300 mg every 2 wk for the 1st 8 wk, then 300 mg every 2 wk as maintenance therapy.
IM (Adults Debilitated or Nonsmoking Female Patients ≥65 yr): Initiate therapy at 150 mg every 4 wk.

Acute Manic or Mixed Episodes Associated With Bipolar I Disorder

PO (Adults ): 10–15 mg/day initially (use 10 mg/day when used with lithium or evaporate); may ↑ every 24 hr by 5 mg/day (not to exceed 20 mg/day).
PO (Children 13–17 yr): 2.5–5 mg/day initially; may ↑ by 2.5–5 mg/day (target dose = 10 mg/day; not to exceed 20 mg/day).

Maintenance Treatment of Bipolar I Disorder

PO (Adults ): Continue at the dose required to maintain symptom remission (usual dose: 5–20 mg/day).
PO (Children 13–17 yr): Continue at the lowest dose required to maintain symptom remission.

Acute Agitation Due to Schizophrenia or Bipolar I Mania

IM (Adults ): 10 mg; may repeat in 2 hr and then 4 hr later.
IM (Adults >65 yr): Initiate therapy with 5 mg.

Depressive Episodes Associated With Bipolar I Disorder

PO (Adults ): 5 mg/day with fluoxetine 20 mg/day (both given in evening); may ↑ fluoxetine dose up to 50 mg/day and olanzapine dose up to 12.5 mg/day.
PO (Children 10–17 yr): 20 mg/day with olanzapine 2.5 mg/day (both given in evening); may ↑ fluoxetine dose up to 50 mg/day and olanzapine dose up to 12 mg/day.

Treatment-Resistant Depression

PO (Adults ): 5 mg/day with fluoxetine 20 mg/day (both given in evening); may ↑ fluoxetine dose up to 50 mg/day and olanzapine dose up to 20 mg/day.

(Generic available)

Tablets: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 15 mg; 20 mg
Orally disintegrating tablets (Zyprexa Zydis): 5 mg; 10 mg; 15 mg; 20 mg
Powder for injection: 10 mg/vial
Extended-release powder for suspension for injection (Zyprexa Relprevv): 210 mg/vial; 300 mg/vial; 405 mg/vial
In combination with:
fluoxetine (generic only); samidorphan (Lybalvi). See Combination Drugs.

Assess mental status (orientation, mood, behavior) before and periodically during therapy. Monitor closely for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression.
- Monitor BP (sitting, standing, lying), ECG, HR, and respiratory rate before and frequently during dose adjustment.
- Assess weight and BMI initially and throughout therapy.
- Observe patient carefully when administering medication to ensure that medication is taken and not hoarded or cheeked.
- Assess fluid intake and bowel function. ↑ of fiber and fluids may help minimize constipation.
- Monitor patient for onset of akathisia (restlessness or desire to keep moving) and extrapyramidal side effects (parkinsonian: difficulty speaking or swallowing, loss of balance control, pill rolling of hands, masklike face, shuffling gait, rigidity, tremors; and dystonic: muscle spasms, twisting motions, twitching, inability to move eyes, weakness of arms or legs) every 2 mo during therapy and 8–12 wk after therapy has been discontinued. Report these symptoms if they occur, as ↓ in dose or discontinuation of medication may be necessary. Trihexyphenidyl or benztropine may be used to control symptoms.
- Monitor for tardive dyskinesia (uncontrolled rhythmic movement of mouth, face, and extremities; lip smacking or puckering; puffing of cheeks; uncontrolled chewing; rapid or worm-like movements of tongue; excessive blinking of eyes). Discontinue olanzapine and report immediately; may be irreversible.
- Monitor for development of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, seizures, diaphoresis, hypertension or hypotension, pallor, tiredness, severe muscle stiffness, loss of bladder control). Notify health care provider immediately if these symptoms occur.
Monitor for symptoms related to hyperprolactinemia (menstrual abnormalities, galactorrhea, sexual dysfunction).
Assess for falls risk. Drowsiness, orthostatic hypotension, and motor and sensory instability ↑ risk. Institute prevention if indicated.
Monitor for signs and symptoms of DRESS (fever, rash, lymphadenopathy, facial swelling), associated with involvement of other organ systems (hepatitis, nephritis, hematologic abnormalities, myocarditis, myositis) during therapy. May resemble an acute viral infection. Eosinophilia is often present. Discontinue therapy if signs occur.
Zyprexa Relprevv: Observe for signs and symptoms of postinjection delirium/sedation syndrome (dizziness, confusion, disorientation, slurred speech, altered gait, difficulty ambulating, weakness, agitation, extrapyramidal symptoms, hypertension, convulsion, reduced level of consciousness ranging from mild sedation to coma) for ≥3 hr after injection.

Lab Test Considerations:

Monitor liver function tests, and ocular examinations periodically during therapy. May ↑ bilirubin, AST, ALT, GGT, CK, and alkaline phosphatase.
- Monitor blood glucose before and periodically during therapy.
- Monitor serum prolactin before and periodically during therapy. May ↑ serum prolactin levels.
- Monitor CBC frequently during initial months of therapy in patients with pre-existing or history of low WBC. May cause leukopenia, neutropenia, or agranulocytosis. Discontinue therapy if this occurs.
- May cause hyperlipidemia; monitor serum lipids before and periodically during therapy.

Do not confuse Zyprexa with Celexa, Zyrtec, Zestril, or Zelapar. Do not confuse olanzapine with quetiapine.
REMS: Zyprexa Relprevv is only prescribed through Zyprexa Relprevv Patient Care Program. Prescribers, pharmacies, and patients must be educated about the program and must comply with the program requirements.
PO: Administer without regard to meals.
- For orally disintegrating tablets, peel back foil on blister; do not push tablet through foil. Using dry hands, remove from foil and place entire tablet in mouth. Tablet will disintegrate with or without liquid.
IM: Reconstitution: Reconstitute with 2.1 mL of sterile water for injection. Solution should be clear and yellow; do not administer solutions that are discolored or contain particulate matter. Concentration: 5 mg/mL. Inject slowly, deep into muscle. Do not administer IV or SUBQ. Administer within 1 hr of reconstitution. Discard unused solution.
- Zyprexa Relprevv: Use gloves when preparing; solution may be irritating to skin. Reconstitution: Use only diluent provided by manufacturer. Reconstitute 150-mg or 210-mg dose with 1.3 mL, 300-mg dose with 1.8 mL, and 405-mg dose with 2.3 mL of diluent. Loosen powder by tapping vial; inject diluent into powder. Remove needle from vial, holding vial upright to prevent loss of solution. Engage needle safety device as explained by manufacturer. Pad a hard surface and tap vial repeatedly until no powder or dry yellow clumps are visible. Shake vial vigorously until suspension appears smooth and consistent in color and texture. Solution will be yellow and opaque. Allow foam to dissipate. Suspension is stable for 24 hr at room temperature; if not used immediately, shake to resuspend. Concentration: 150 mg/mL. Replace needle with 19-gauge, 1½-inch or 2-inch needle for obese patients. Slowly withdraw desired amount from vial; 150 mg = 1 mL, 210 mg = 1.4 mL, 300 mg = 2 mL, 405 mg = 2.7 mL. Administer immediately deep IM gluteal after withdrawing. Do not massage injection site. Patient must be observed for ≥3 hr after injection for postinjection delirium/sedation syndrome.

REMS: Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Advise to take as directed and not to skip doses or double up on missed doses. May need to discontinue gradually. Explain the Zyprexa Relprevv Patient Care Program to patient and encourage patient to enroll in the Zyprexa Relprevv Patient Care Program registry.
Emphasize the importance of routine follow-up exams and continued participation in psychotherapy.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications and alcohol.
Advise patient of possibility of extrapyramidal symptoms and tardive dyskinesia. Advise patient to report these symptoms immediately to health care provider.
Advise patient to change positions slowly to minimize orthostatic hypotension. Protect from falls.
Medication may cause drowsiness. Advise patient to avoid driving or other activities requiring alertness until response to the medication is known. Patients receiving Zyprexa Relprevv should not drive for 24 hr following injection.
Advise patient and family/caregiver to notify health care provider if thoughts about suicide or dying, attempts to commit suicide, new or worse depression, new or worse anxiety, feeling very agitated or restless, panic attacks, trouble sleeping, new or worse irritability, acting aggressive, being angry or violent, acting on dangerous impulses, an extreme ↑ in activity and talking, or other unusual changes in behavior or mood occur.
Advise patient to use sunscreen and protective clothing when exposed to the sun. Extremes of temperature (exercise, hot weather, hot baths or showers) should also be avoided; this drug impairs body temperature regulation.
Advise patient to use saliva substitute, frequent mouth rinses, good oral hygiene, and sugarless gum or candy to minimize dry mouth. Consult dentist if dry mouth continues for >2 wk.
Advise patient to notify health care provider of medication regimen before treatment or surgery.
Advise patient to notify health care provider promptly if sore throat, fever, unusual bleeding or bruising, rash, symptoms of postinjection delirium/sedation syndrome, weakness, tremors, visual disturbances, dark-colored urine, clay-colored stools, menstrual abnormalities, galactorrhea, or sexual dysfunction occur.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected and to avoid breastfeeding during therapy. Encourage women who become pregnant while taking olanzapine to enroll in the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit https://womensmentalhealth.org/research/pregnancyregistry/. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Monitor infants exposed through breastfeeding for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements).

Decreased manifestations of psychoses.

ZyPREXA, ZyPREXA Relprevv, ZyPREXA Zydis

NDC Code

0002- Eli Lilly and Company
- 0002-4112- Zyprexa
  - 0002-4112-30- 30 TABLET in 1 BOTTLE (0002-4112-30)

0002- Eli Lilly and Company
- 0002-4115- Zyprexa
  - 0002-4115-30- 30 TABLET in 1 BOTTLE (0002-4115-30)

0002- Eli Lilly and Company
- 0002-4116- Zyprexa
  - 0002-4116-30- 30 TABLET in 1 BOTTLE (0002-4116-30)

0002- Eli Lilly and Company
- 0002-4117- Zyprexa
  - 0002-4117-30- 30 TABLET in 1 BOTTLE (0002-4117-30)

0002- Eli Lilly and Company
- 0002-4415- Zyprexa
  - 0002-4415-30- 30 TABLET in 1 BOTTLE (0002-4415-30)

0002- Eli Lilly and Company
- 0002-4420- Zyprexa
  - 0002-4420-30- 30 TABLET in 1 BOTTLE (0002-4420-30)

0002- Eli Lilly and Company
- 0002-4453- ZYPREXA Zydis
  - 0002-4453-85- 30 DOSE PACK in 1 CARTON (0002-4453-85) / 1 BLISTER PACK in 1 DOSE PACK (0002-4453-01) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

0002- Eli Lilly and Company
- 0002-4454- ZYPREXA Zydis
  - 0002-4454-85- 30 DOSE PACK in 1 CARTON (0002-4454-85) / 1 BLISTER PACK in 1 DOSE PACK (0002-4454-01) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

0002- Eli Lilly and Company
- 0002-4455- ZYPREXA Zydis
  - 0002-4455-85- 30 DOSE PACK in 1 CARTON (0002-4455-85) / 1 BLISTER PACK in 1 DOSE PACK (0002-4455-01) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

0002- Eli Lilly and Company
- 0002-4456- ZYPREXA Zydis
  - 0002-4456-85- 30 DOSE PACK in 1 CARTON (0002-4456-85) / 1 BLISTER PACK in 1 DOSE PACK (0002-4456-01) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

0002- Eli Lilly and Company
- 0002-7597- ZYPREXA Intramuscular
  - 0002-7597-01- 1 VIAL in 1 CARTON (0002-7597-01) / 2 mL in 1 VIAL

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5245- Olanzapine
  - 0093-5245-65- 30 BLISTER PACK in 1 CARTON (0093-5245-65) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5245-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5246- Olanzapine
  - 0093-5246-65- 30 BLISTER PACK in 1 CARTON (0093-5246-65) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5246-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5247- Olanzapine
  - 0093-5247-65- 30 BLISTER PACK in 1 CARTON (0093-5247-65) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5247-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5248- Olanzapine
  - 0093-5248-65- 30 BLISTER PACK in 1 CARTON (0093-5248-65) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5248-19)

0110- Lilly del Caribe, Inc.
- 0110-4112-
  - 0110-4112-06- 269000 TABLET in 1 DRUM (0110-4112-06)

0110- Lilly del Caribe, Inc.
- 0110-4115-
  - 0110-4115-06- 175000 TABLET in 1 DRUM (0110-4115-06)

0110- Lilly del Caribe, Inc.
- 0110-4116-
  - 0110-4116-06- 117000 TABLET in 1 DRUM (0110-4116-06)

0110- Lilly del Caribe, Inc.
- 0110-4117-
  0110-4117-06- 87500 TABLET in 1 DRUM (0110-4117-06)

0110- Lilly del Caribe, Inc.
- 0110-4415-
  0110-4415-06- 146000 TABLET in 1 DRUM (0110-4415-06)

0110- Lilly del Caribe, Inc.
- 0110-4420-
  0110-4420-06- 109500 TABLET in 1 DRUM (0110-4420-06)

0121- PAI Holdings, LLC dba PAI Pharma
- 0121-1072- Olanzapine Intramuscular
  0121-1072-55- 1 VIAL in 1 CARTON (0121-1072-55) / 2 mL in 1 VIAL

0143- Hikma Pharmaceuticals USA Inc.
- 0143-9199- Olanzapine
  - 0143-9199-01- 1 VIAL in 1 CARTON (0143-9199-01) / 2 mL in 1 VIAL

0378- Mylan Pharmaceuticals Inc.
- 0378-5510- Olanzapine
  - 0378-5510-93- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-5510-93)

0378- Mylan Pharmaceuticals Inc.
- 0378-5511- Olanzapine
  - 0378-5511-93- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-5511-93)

0378- Mylan Pharmaceuticals Inc.
- 0378-5512- Olanzapine
  - 0378-5512-93- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-5512-93)

0378- Mylan Pharmaceuticals Inc.
- 0378-5513- Olanzapine
  - 0378-5513-93- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-5513-93)

0517- American Regent, Inc.
- 0517-0955- Olanzapine
  - 0517-0955-01- 1 VIAL, GLASS in 1 CARTON (0517-0955-01) / 2 mL in 1 VIAL, GLASS

0527- Lannett Company, Inc.
- 0527-3161- Olanzapine
  - 0527-3161-32- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0527-3161-32)

0527- Lannett Company, Inc.
- 0527-3162- Olanzapine
  - 0527-3162-32- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0527-3162-32)

0527- Lannett Company, Inc.
- 0527-3163- Olanzapine
  - 0527-3163-32- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0527-3163-32)

0527- Lannett Company, Inc.
- 0527-3164- Olanzapine
  - 0527-3164-32- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0527-3164-32)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8243- Olanzapine
  - 0615-8243-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8243-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8244- Olanzapine
  - 0615-8244-05- 15 TABLET, FILM COATED in 1 BLISTER PACK (0615-8244-05)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8244- Olanzapine
  - 0615-8244-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8244-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8245- Olanzapine
  - 0615-8245-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8245-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8246- Olanzapine
  - 0615-8246-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8246-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8566- Olanzapine
  - 0615-8566-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8566-39)

0781- Sandoz Inc
- 0781-3159- Olanzapine
  - 0781-3159-72- 1 VIAL in 1 CARTON (0781-3159-72) / 2 mL in 1 VIAL

0781- Sandoz Inc
- 0781-9105- Olanzapine
  - 0781-9105-72- 1 VIAL in 1 CARTON (0781-9105-72) / 2 mL in 1 VIAL

0832- Upsher-Smith Laboratories, LLC
- 0832-6078- Olanzapine
  - 0832-6078-03- 30 TABLET in 1 BOTTLE (0832-6078-03)

0832- Upsher-Smith Laboratories, LLC
- 0832-6078- Olanzapine
  - 0832-6078-50- 500 TABLET in 1 BOTTLE (0832-6078-50)

0832- Upsher-Smith Laboratories, LLC
- 0832-6079- Olanzapine
  - 0832-6079-03- 30 TABLET in 1 BOTTLE (0832-6079-03)

0832- Upsher-Smith Laboratories, LLC
- 0832-6079- Olanzapine
  - 0832-6079-50- 500 TABLET in 1 BOTTLE (0832-6079-50)

0832- Upsher-Smith Laboratories, LLC
- 0832-6080- Olanzapine
  - 0832-6080-03- 30 TABLET in 1 BOTTLE (0832-6080-03)

0832- Upsher-Smith Laboratories, LLC
- 0832-6080- Olanzapine
  - 0832-6080-50- 500 TABLET in 1 BOTTLE (0832-6080-50)

0832- Upsher-Smith Laboratories, LLC
- 0832-6081- Olanzapine
  - 0832-6081-03- 30 TABLET in 1 BOTTLE (0832-6081-03)

0832- Upsher-Smith Laboratories, LLC
- 0832-6081- Olanzapine
  - 0832-6081-50- 500 TABLET in 1 BOTTLE (0832-6081-50)

0832- Upsher-Smith Laboratories, LLC
- 0832-6082- Olanzapine
  - 0832-6082-03- 30 TABLET in 1 BOTTLE (0832-6082-03)

0832- Upsher-Smith Laboratories, LLC
- 0832-6082- Olanzapine
  - 0832-6082-50- 500 TABLET in 1 BOTTLE (0832-6082-50)

0832- Upsher-Smith Laboratories, LLC
- 0832-6083- Olanzapine
  - 0832-6083-03- 30 TABLET in 1 BOTTLE (0832-6083-03)

0832- Upsher-Smith Laboratories, LLC
- 0832-6083- Olanzapine
  - 0832-6083-50- 500 TABLET in 1 BOTTLE (0832-6083-50)

0904- Major Pharmaceuticals
- 0904-6286- Olanzapine
  - 0904-6286-61- 100 BLISTER PACK in 1 CARTON (0904-6286-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-6287- Olanzapine
  - 0904-6287-06- 50 BLISTER PACK in 1 CARTON (0904-6287-06) / 1 TABLET, FILM COATED in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-6287- Olanzapine
  - 0904-6287-61- 100 BLISTER PACK in 1 CARTON (0904-6287-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-6376- Olanzapine
  - 0904-6376-61- 100 BLISTER PACK in 1 CARTON (0904-6376-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-6377- Olanzapine
  - 0904-6377-61- 100 BLISTER PACK in 1 CARTON (0904-6377-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

12651- Cambrex Karlskoga AB
- 12651-125-
  - 12651-125-00- 4 kg in 1 DRUM (12651-125-00)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-01- 33 kg in 1 DRUM (12651-125-01)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-02- 34 kg in 1 DRUM (12651-125-02)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-03- 50 kg in 1 DRUM (12651-125-03)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-04- 5 kg in 1 DRUM (12651-125-04)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-05- 25 kg in 1 DRUM (12651-125-05)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-06- 45 kg in 1 DRUM (12651-125-06)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-17- 17 kg in 1 DRUM (12651-125-17)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-19- 19 kg in 1 DRUM (12651-125-19)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-21- 21 kg in 1 DRUM (12651-125-21)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-22- 22 kg in 1 DRUM (12651-125-22)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-30- 30 kg in 1 DRUM (12651-125-30)

12651- Cambrex Karlskoga AB
- 12651-125-
  12651-125-51- 51 kg in 1 DRUM (12651-125-51)

13668- Torrent Pharmaceuticals Limited
- 13668-086- OLANZAPINE
  13668-086-05- 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-086-05)

13668- Torrent Pharmaceuticals Limited
- 13668-086- OLANZAPINE
  - 13668-086-30- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-086-30)

13668- Torrent Pharmaceuticals Limited
- 13668-086- OLANZAPINE
  - 13668-086-90- 90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-086-90)

13668- Torrent Pharmaceuticals Limited
- 13668-088- OLANZAPINE
  - 13668-088-05- 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-088-05)

13668- Torrent Pharmaceuticals Limited
- 13668-088- OLANZAPINE
  - 13668-088-30- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-088-30)

13668- Torrent Pharmaceuticals Limited
- 13668-088- OLANZAPINE
  - 13668-088-90- 90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-088-90)

13668- Torrent Pharmaceuticals Limited
- 13668-089- OLANZAPINE
  - 13668-089-05- 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-089-05)

13668- Torrent Pharmaceuticals Limited
- 13668-089- OLANZAPINE
  - 13668-089-30- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-089-30)

13668- Torrent Pharmaceuticals Limited
- 13668-089- OLANZAPINE
  - 13668-089-90- 90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-089-90)

13668- Torrent Pharmaceuticals Limited
- 13668-090- OLANZAPINE
  - 13668-090-05- 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-090-05)

13668- Torrent Pharmaceuticals Limited
- 13668-090- OLANZAPINE
  - 13668-090-30- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-090-30)

13668- Torrent Pharmaceuticals Limited
- 13668-090- OLANZAPINE
  - 13668-090-90- 90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (13668-090-90)

14445- Indoco Remedies Limited
- 14445-106- Olanzapine
  - 14445-106-00- 1000 TABLET in 1 BOTTLE (14445-106-00)

14445- Indoco Remedies Limited
- 14445-106- Olanzapine
  - 14445-106-10- 100 TABLET in 1 BLISTER PACK (14445-106-10)

14445- Indoco Remedies Limited
- 14445-106- Olanzapine
  - 14445-106-30- 30 TABLET in 1 BOTTLE (14445-106-30)

14445- Indoco Remedies Limited
- 14445-107- Olanzapine
  - 14445-107-00- 1000 TABLET in 1 BOTTLE (14445-107-00)

14445- Indoco Remedies Limited
- 14445-107- Olanzapine
  - 14445-107-10- 100 TABLET in 1 BLISTER PACK (14445-107-10)

14445- Indoco Remedies Limited
- 14445-107- Olanzapine
  - 14445-107-30- 30 TABLET in 1 BOTTLE (14445-107-30)

14445- Indoco Remedies Limited
- 14445-108- Olanzapine
  - 14445-108-00- 1000 TABLET in 1 BOTTLE (14445-108-00)

14445- Indoco Remedies Limited
- 14445-108- Olanzapine
  - 14445-108-10- 100 TABLET in 1 BLISTER PACK (14445-108-10)

14445- Indoco Remedies Limited
- 14445-108- Olanzapine
  - 14445-108-30- 30 TABLET in 1 BOTTLE (14445-108-30)

14445- Indoco Remedies Limited
- 14445-109- Olanzapine
  - 14445-109-00- 1000 TABLET in 1 BOTTLE (14445-109-00)

14445- Indoco Remedies Limited
- 14445-109- Olanzapine
  - 14445-109-10- 100 TABLET in 1 BLISTER PACK (14445-109-10)

14445- Indoco Remedies Limited
- 14445-109- Olanzapine
  - 14445-109-30- 30 TABLET in 1 BOTTLE (14445-109-30)

14445- Indoco Remedies Limited
- 14445-110- Olanzapine
  - 14445-110-00- 1000 TABLET in 1 BOTTLE (14445-110-00)

14445- Indoco Remedies Limited
- 14445-110- Olanzapine
  - 14445-110-10- 100 TABLET in 1 BLISTER PACK (14445-110-10)

14445- Indoco Remedies Limited
- 14445-110- Olanzapine
  - 14445-110-30- 30 TABLET in 1 BOTTLE (14445-110-30)

14445- Indoco Remedies Limited
- 14445-111- Olanzapine
  - 14445-111-00- 1000 TABLET in 1 BOTTLE (14445-111-00)

14445- Indoco Remedies Limited
- 14445-111- Olanzapine
  - 14445-111-10- 100 TABLET in 1 BLISTER PACK (14445-111-10)

14445- Indoco Remedies Limited
- 14445-111- Olanzapine
  - 14445-111-30- 30 TABLET in 1 BOTTLE (14445-111-30)

14799- Zhejiang Supor Pharmaceuticals Co., Ltd
- 14799-2010-
  - 14799-2010-1- 25 kg in 1 DRUM (14799-2010-1)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Pill Image

Code ⬆